{"id":360766,"date":"2026-04-14T18:31:13","date_gmt":"2026-04-14T13:01:13","guid":{"rendered":"https:\/\/forumias.com\/blog\/?p=360766"},"modified":"2026-04-14T18:31:13","modified_gmt":"2026-04-14T13:01:13","slug":"india-moving-up-the-pharma-value-chain","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/india-moving-up-the-pharma-value-chain\/","title":{"rendered":"India Moving Up the Pharma Value Chain"},"content":{"rendered":"

UPSC Syllabus: Gs Paper 3- <\/strong>Indian economy<\/p>\n

Introduction<\/strong><\/h2>\n

India has emerged as the \u201cPharmacy of the World\u201d through affordable and quality generic medicines. However, biologics, biosimilars, and specialty drugs now account for over 40% of global pharmaceutical revenues. This shift is pushing India to move up the pharma value chain towards innovation and high-value therapeutics. Government policies are now focused on building scientific capacity, strengthening research, and expanding advanced manufacturing, while ensuring affordability and maintaining global leadership in generic drug supply.<\/p>\n

Current Status of India\u2019s Pharma Industry<\/strong><\/h2>\n
    \n
  1. Global leadership in generics and vaccines: <\/strong>India supplies around 20% of global generic medicines and leads in vaccines like Diphtheria, Tetanus, Pertussis (DPT), Bacillus Calmette\u2013Gu\u00e9rin (BCG), and measles.<\/li>\n
  2. Strong industrial base and scale: <\/strong>The industry ranks 3rd globally by volume and 11th by value, with over 3,000 companies and 10,500 manufacturing units.<\/li>\n
  3. Growing domestic market and turnover: <\/strong>The domestic market is valued at USD 60 billion and is expected to reach USD 130 billion by 2030, with turnover of \u20b94.72 lakh crore in FY25.<\/li>\n
  4. Export expansion and global reach: <\/strong>Pharmaceutical exports reached USD 30.5 billion in 2024-25, with exports to 191 countries, showing strong global demand.<\/li>\n
  5. Presence in regulated markets: <\/strong>Around 50% of exports go to regulated markets like the United States and Europe, reflecting high quality standards.<\/li>\n
  6. Diversified export destinations: <\/strong>Exports are spread across countries like Nigeria, Brazil, Saudi Arabia, and France, reducing dependence on limited markets.<\/li>\n
  7. Rising foreign investment: <\/strong>The sector attracts strong Foreign Direct Investment (FDI), with inflows of \u20b913,193 crore in 2025-26, showing investor confidence.<\/li>\n
  8. API manufacturing strength: <\/strong>India has around 500 Active Pharmaceutical Ingredient (API) manufacturers, contributing nearly 8% of the global API industry.<\/li>\n<\/ol>\n

    Transition Towards Innovation and Value Addition<\/strong><\/h2>\n
      \n
    1. Shift from generics to innovation: <\/strong>The industry is moving from generic drug manufacturing to innovation-driven drug discovery and advanced therapies.<\/li>\n
    2. Biopharma SHAKTI initiative: <\/strong>The Strategy for Healthcare Advancement through Knowledge, Technology and Innovation (SHAKTI) with an outlay of \u20b910,000 crore aims to build capacity in biologics and biosimilars.<\/li>\n
    3. Strengthening R&D ecosystem: <\/strong>Schemes like Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) and BioNEST support research and innovation.<\/li>\n
    4. Focus on scientific capability: <\/strong>Efforts are being made to build deep scientific research capacity and innovation-based enterprises.<\/li>\n<\/ol>\n

      Domestic Manufacturing and Research Capacity<\/strong><\/h2>\n
        \n
      1. Fermentation-based manufacturing push: <\/strong>India is strengthening fermentation-based manufacturing for antibiotics, vaccines, enzymes, and biologics to reduce long-standing import dependence.<\/li>\n
      2. API and KSM localisation: <\/strong>Production Linked Incentive (PLI) schemes and Bulk Drug Parks are expanding domestic capacity for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs).<\/li>\n
      3. Clinical trial ecosystem expansion: <\/strong>The plan to establish 1,000 accredited clinical trial sites will strengthen India\u2019s position in global drug development.<\/li>\n
      4. Cost advantage and skilled workforce: <\/strong>India offers low-cost clinical trials and skilled investigators, making it an attractive destination for research.<\/li>\n<\/ol>\n

        Government Initiatives and Policy Support<\/strong><\/h2>\n
          \n
        1. PLI schemes for manufacturing growth: <\/strong>Production Linked Incentive (PLI) schemes have reduced imports by \u20b93,591 crore and strengthened domestic manufacturing.<\/li>\n
        2. Bulk drug and medical device parks: <\/strong>Three bulk drug parks and three medical device parks are being developed to improve infrastructure.<\/li>\n
        3. PRIP and research promotion: <\/strong>Under Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), 7 Centres of Excellence and over 111 research projects support innovation.<\/li>\n
        4. Affordable medicine access: <\/strong>The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)runs over 18,000 Jan Aushadhi Kendras, reducing medicine costs.<\/li>\n
        5. Trade agreements boosting exports: <\/strong>Agreements with the European Union (EU), United Kingdom (UK), and New Zealand provide better market access.<\/li>\n<\/ol>\n

          Regulatory Strength and Quality Assurance<\/strong><\/h2>\n
            \n
          1. Strong regulatory institutions: <\/strong>The Central Drugs Standard Control Organisation (CDSCO)regulates drugs and clinical trials to ensure safety and quality.<\/li>\n
          2. Drug pricing and monitoring: <\/strong>The National Pharmaceutical Pricing Authority (NPPA) controls drug prices under the Drugs Prices Control Order (DPCO), 2013.<\/li>\n
          3. Standardisation and pharmacopoeia: <\/strong>The Indian Pharmacopoeia Commission (IPC) sets standards for drug quality and is recognised in 19 countries.<\/li>\n
          4. Global confidence in quality: <\/strong>India has the highest number of United States Food and Drug Administration (USFDA) approved plants outside the USA.<\/li>\n
          5. Regulatory reforms for ease of business: <\/strong>Digitalisation, faster approvals, and harmonisation improve efficiency and global competitiveness.<\/li>\n<\/ol>\n

            Key Challenges<\/strong><\/h2>\n
              \n
            1. Low R&D investment: <\/strong>Investment in research and development is still low, affecting innovation capacity.<\/li>\n
            2. Need for stronger collaboration: <\/strong>More public-private partnerships are required to sustain innovation and research.<\/li>\n
            3. Import dependence in key areas: <\/strong>Some segments like fermentation-based products still rely on imports.<\/li>\n
            4. Balancing innovation with affordability: <\/strong>Advanced therapies may increase costs, so ensuring affordable access remains important.<\/li>\n<\/ol>\n

              Conclusion<\/strong><\/h2>\n

              India\u2019s pharmaceutical sector is steadily moving up the value chain from generics to innovation-driven growth. Strong policy support, expanding research capacity, and rising global integration are enabling this transition. With focus on advanced therapeutics, domestic manufacturing, and affordability, India is well positioned to emerge as a global leader in biopharma innovation while sustaining its role as a reliable supplier of essential medicines.<\/p>\n

              Question for practice:<\/strong><\/h2>\n

              Evaluate how India is moving up the pharmaceutical value chain towards innovation-driven growth.<\/p>\n

              Source<\/strong>: Businessline <\/strong><\/a>and<\/strong> PIB<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

              UPSC Syllabus: Gs Paper 3- Indian economy Introduction India has emerged as the \u201cPharmacy of the World\u201d through affordable and quality generic medicines. However, biologics, biosimilars, and specialty drugs now account for over 40% of global pharmaceutical revenues. This shift is pushing India to move up the pharma value chain towards innovation and high-value therapeutics.… Continue reading India Moving Up the Pharma Value Chain<\/span><\/a><\/p>\n","protected":false},"author":10320,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[1230],"tags":[12121,216,8184],"class_list":["post-360766","post","type-post","status-publish","format-standard","hentry","category-9-pm-daily-articles","tag-businessline","tag-gs-paper-3","tag-indian-economy","entry"],"jetpack_featured_media_url":"","views":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/360766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/10320"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=360766"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/360766\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=360766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=360766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=360766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}